UNSPSC 85266303: Diagnosis of secondary systemic amyloidosis

This classification denotes the group of activities that yields a diagnosis of Secondary systemic amyloidosis. Secondary systemic amyloidosis is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code E85. 3

UNSPSC 85266303 Diagnosis of secondary systemic amyloidosis is a Commodity code that shows a significant mismatch between its nominal scope — diagnosis and clinical testing for a specific systemic disease — and the state and local opportunities currently tagged to it. The recent solicitations indexed under this code include a diagnostic imaging PACS system implementation at a county hospital, special education contracted services across a school district, and a temporary health professional staffing pool for a county health system. None of these opportunities directly address amyloidosis diagnosis or specialist clinical testing services. The code appears to capture health system procurements broadly without precise alignment to its stated commodity description, suggesting either classification drift in state and local systems or inconsistent tagging across issuing bodies.

The recent activity spans two states — California (San Mateo County Medical Center and Santa Clara County Health System) and Texas (Birdville Independent School District) — with the California health systems posting diagnostic and staffing requests in July and October 2026, and the school district posting special education services in September 2026. The San Mateo Medical Center RFP for Diagnostic Imaging PACS (due October 21, 2026) is the only solicitation with direct relevance to diagnostic capabilities, but it focuses on enterprise imaging infrastructure for radiology, cardiology, and mammography rather than amyloidosis-specific diagnostics. The code shows little relevant recent activity for vendors specializing in amyloidosis diagnosis or secondary systemic amyloidosis screening services; a business development professional evaluating state and local procurement under this code should verify the intended commodity scope with issuing bodies before pursuit, as the current tagging does not reflect a clear market for amyloidosis-specific diagnostic contracting.